Leadership & Pay ·
Quince Therapeutics announced that President Charles Ryan will depart the company on September 8, 2026
QNCXIRulya Therapeutics Inc.
Quince Therapeutics announced that President Charles Ryan will depart the company on September 8, 2026. Mr. Ryan is eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023. The filing does not disclose specific monetary amounts or identify a successor officer at this time. Quince Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases.